United Therapeutics Corporation Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹23.9K Cr
- United Therapeutics projects a $4 billion revenue run rate by the end of 2027, more than doubling current revenues. - United Therapeutics aims to reach a $4 billion revenue run rate by the end of 2027, more than doubling current revenues.
From United Therapeutics Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹562.09
Market Cap
₹23.9K Cr
P/E Ratio
21.4
Revenue Rank
Margin Rank
How does United Therapeutics Corporation rank in Biotechnology?
Compare United Therapeutics Corporation against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 1- →United Therapeutics projects a $4 billion revenue run rate by the end of 2027, more than doubling current revenues.
- →Ralinepag and the IPF indication alone are expected to drive this growth.
- →The launch of oral ralinepag is anticipated by mid-next year, assuming smooth FDA approval.
- →Tyvaso DPI has shown 9% year-over-year growth, driven by increased patient demand.
- →New formulations like Tyvaso DPI, Tyvaso SMI, and ralinepag DPI are expected to expand market reach in PH-ILD, PAH, IPF, and PPF.
- →The company plans to invest in commercial sales force expansion mid-year to focus on capturing uncaptured markets.
- →Patient shipments and prescriber engagement have steadily increased in recent months.
- →The organization aims for sustained double-digit long-term growth fueled by innovation and expanded product offerings.
📈 Profitability & Margins
Rank 3- →United Therapeutics aims to reach a $4 billion revenue run rate by the end of 2027, more than doubling current revenues.
- →The launch of ralinepag and multiple formulations of Tyvaso (nebulized, DPI, and SMI) is expected to drive significant growth.
- →Ralinepag, as a once-daily oral prostacyclin, is anticipated to become the most prescribed prostacyclin for PAH, contributing strongly to revenue.
- →The IPF indication, with Tyvaso and its DPI and SMI forms, is also projected as a major revenue driver, with expectations to become the most prescribed therapy for IPF.
- →The company plans to expand commercial efforts mid-2026 to capture more of the PH-ILD and PAH markets.
- →Double-digit long-term growth in earnings and profits is anticipated, supported by a durable, high-performing commercial engine and ongoing product innovation.
🏗️ Capital Expenditure Plans
Yes- →United Therapeutics is investing in expanding manufacturing capacity to support the growing demand for Tyvaso DPI and ralinepag.
- →They will utilize the Danbury, Connecticut MannKind production plant and the new United Therapeutics North Carolina DPI facility.
- →Sales force investments are planned to be deployed mid-2026 to expand reach and capture more of the addressable PH-ILD and PAH markets.
- →Continued development and commercial scale-up of multiple product formulations (DPI, SMI, nebulized) for various indications including IPF and PAH.
- →Ongoing regulatory and clinical development investments to support new product filings and launches, like ralinepag oral and inhaled formulations.
- →Leveraging MannKind’s crystal carrier IP for ralinepag solid dose and DPI formulations, indicating strategic collaboration investment.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
No information- →The company expects a strong demand trajectory, aiming for a $4 billion revenue run rate by the end of 2027, more than doubling current revenues driven by ralinepag and IPF indications.
- →There is significant patient demand for Tyvaso DPI, with patient shipments growing for the last 5 months and increased patient graduation to higher doses.
- →The launch of ralinepag oral formulation is expected mid-next year following anticipated FDA approval, targeting a multibillion-dollar market opportunity.
- →Preparations for product launches, including IPF indications and ralinepag formulations, are underway with expanded sales force investments planned for mid-2026.
- →The company anticipates tens of thousands of treated patients across PAH, ILD, IPF, and PPF indications, utilizing full capacity of manufacturing facilities.
- →They expect to complete Phase I studies for new formulations (e.g., ralinepag DPI) by end of the year and rapidly proceed to efficacy studies, positioning their orderbook favorably.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Frequently Asked Questions
What were United Therapeutics Corporation Q2 FY26 results?
- United Therapeutics projects a $4 billion revenue run rate by the end of 2027, more than doubling current revenues. - United Therapeutics aims to reach a $4 billion revenue run rate by the end of 2027, more than doubling current revenues.
What is United Therapeutics Corporation share price analysis?
United Therapeutics Corporation currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 21.4 with a market cap of $23,859. Investors should review the full earnings analysis for detailed insights.
Is United Therapeutics Corporation planning capital expenditure?
- United Therapeutics is investing in expanding manufacturing capacity to support the growing demand for Tyvaso DPI and ralinepag.
Keep United Therapeutics Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.